Welcome to our dedicated page for BeiGene, Ltd. American Depositary Shares news (Ticker: BGNE), a resource for investors and traders seeking the latest updates and insights on BeiGene, Ltd. American Depositary Shares stock.
BeiGene, Ltd. (NASDAQ: BGNE) is a global biotechnology company specializing in the development and commercialization of innovative cancer treatments. With a robust portfolio focused on molecularly targeted and immuno-oncology drugs, BeiGene addresses crucial oncology targets such as Bruton's tyrosine kinase (BTK) and the immune checkpoint protein PD-1. The company’s notable products include tislelizumab, a PD-1 inhibitor, and zanubrutinib, a BTK inhibitor, which have shown promising results in treating various cancers. BeiGene’s latest achievements include FDA and European regulatory approvals, significant clinical trial successes, and partnerships aimed at expanding the reach of their therapies globally. The company operates across major markets, including China, the United States, and internationally, striving to make high-quality cancer treatments more accessible. BeiGene’s commitment to advancing global health equity is evident in its innovative drug pipeline and strategic collaborations.
Rhea-AI Summary
BeiGene presents promising data on tislelizumab-containing immuno-oncology combinations and BGB-16673 at AACR 2024, showcasing advancements in cancer treatment and novel mechanisms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
-
Rhea-AI Summary
BeiGene, Ltd. announces a new analysis comparing BRUKINSA and acalabrutinib in CLL, showing potential efficacy advantages for BRUKINSA in progression-free survival, complete response, and overall survival. The MAIC data will be presented at a congress in Miami. BRUKINSA is the only BTK inhibitor to demonstrate superiority over ibrutinib in R/R CLL. Acalabrutinib has shown improvement in progression-free survival in different trials. The analysis suggests BRUKINSA's superiority over acalabrutinib in progression-free survival and complete response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
-
Rhea-AI Summary
BeiGene, Ltd. (BGNE) will participate in fireside chats at two investor conferences, TD Cowen 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference. Live webcasts can be accessed on BeiGene's website, with archived replays available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
Rhea-AI Summary
BeiGene, Ltd. announces FDA acceptance of BLA for TEVIMBRA in combination with chemotherapy for advanced gastric/GEJ cancer treatment. Results from RATIONALE-305 trial show significant overall survival improvement. FDA action date set for December 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.12%
Tags
-
Rhea-AI Summary
BeiGene, Ltd. (BGNE) reports a remarkable year with record revenues, strong hematology leadership, and innovative pipeline progress. The company achieved total revenues of $634 million in Q4 and $2.5 billion in 2023, marking a 67% and 74% increase from the previous year. Key highlights include the success of BRUKINSA, initiation of registrational trials for sonrotoclax, and expansion of the hematology pipeline. Financially, product revenues surged by 86% in Q4 and 75% in 2023, driven by BRUKINSA and tislelizumab sales. Operating expenses increased due to R&D investments, but net loss improved, supported by reduced operating losses. The company's regulatory progress and development programs show promising milestones ahead, reinforcing its position as a global oncology leader.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
-
News
Rhea-AI Summary
BeiGene's tislelizumab receives positive CHMP opinion for NSCLC treatment after successful Phase 3 trials, showing efficacy in treatment-naïve and treatment-resistant patients. The drug is recommended for various NSCLC indications, including as a first- and second-line therapy, with promising results published in reputable medical journals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
Rhea-AI Summary
BeiGene, Ltd. (NASDAQ: BGNE) appoints Olivier Brandicourt, M.D. to its Board of Directors, replacing Thomas Malley. Dr. Brandicourt brings global pharmaceutical and medical leadership experience, aiming to advance the company's mission to bring innovative cancer medicines to more patients around the world.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
-
Rhea-AI Summary
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) announces U.S. label update for BRUKINSA® (zanubrutinib) to include superior progression-free survival results from the Phase 3 ALPINE trial compared to IMBRUVICA® (ibrutinib) in Relapsed or Refractory CLL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
-
Rhea-AI Summary
BeiGene, Ltd. (BGNE) to participate in the 42nd Annual J.P. Morgan Healthcare Conference with a presentation on January 8th, 2024. The live webcast can be accessed from the investors section of BeiGene’s website with archived replays available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
Rhea-AI Summary
BeiGene, Ltd. (BGNE) to host Investor Event at ASH Annual Meeting and Exposition to cover R&D progress and hematology portfolio
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
FAQ
What is the current stock price of BeiGene, Ltd. American Depositary Shares (BGNE)?
The current stock price of BeiGene, Ltd. American Depositary Shares (BGNE) is $189.23 as of November 15, 2024.
What is the market cap of BeiGene, Ltd. American Depositary Shares (BGNE)?
The market cap of BeiGene, Ltd. American Depositary Shares (BGNE) is approximately 19.9B.
What type of company is BeiGene, Ltd.?
BeiGene, Ltd. is a global biotechnology company focused on developing and commercializing innovative cancer treatments.
What are some of BeiGene’s notable products?
Some of BeiGene’s notable products include tislelizumab, a PD-1 inhibitor, and zanubrutinib, a BTK inhibitor.
What markets does BeiGene operate in?
BeiGene operates in major markets including China, the United States, and internationally.
What recent achievements has BeiGene accomplished?
Recent achievements include the FDA and European regulatory approvals for its cancer treatments, significant clinical trial successes, and strategic partnerships.
What are BeiGene’s primary focus areas in oncology?
BeiGene focuses on molecularly targeted and immuno-oncology drugs, addressing targets like BTK and the immune checkpoint protein PD-1.
How does BeiGene contribute to global health equity?
BeiGene contributes to global health equity by developing innovative cancer treatments and forming strategic collaborations to make these therapies more accessible.
What are the financial highlights for BeiGene's latest quarter?
For the latest quarter, BeiGene reported total revenues of $752 million with significant growth in BRUKINSA product sales in the U.S. and Europe.
What is the significance of BeiGene's drug zanubrutinib?
Zanubrutinib is a BTK inhibitor that has shown promising results in treating various cancers, leading to increased market share and regulatory approvals.
What strategic initiatives is BeiGene currently pursuing?
BeiGene is focusing on expanding its global presence, advancing its innovative drug pipeline, and enhancing collaborations to broaden the accessibility of its cancer treatments.
What impact has BeiGene made on cancer treatment accessibility?
BeiGene has made significant strides in making high-quality cancer treatments more accessible globally through innovative drug development and strategic partnerships.
BeiGene, Ltd. American Depositary Shares
Nasdaq:BGNE
BGNE Rankings
BGNE Stock Data
19.88B
1.25B
19.48%
49.53%
1.42%
Biotechnology
Pharmaceutical Preparations
United States of America
GRAND CAYMAN